SOURCE: Active Biotech

February 12, 2009 05:30 ET

Active Biotech AB year End Report January-December 2008

LUND, SWEDEN--(Marketwire - February 12, 2009) -


* Laquinimod -- Phase III Allegro study fully enrolled
* 57-57 -- Phase II/III program only to be initiated in cooperation
  with partner
* RhuDex™ -- additional preclinical trials being performed
* ANYARA -- presentation of data in combination with established
  tumor drug
* TASQ -- Phase II study proceeding as planned
* Net sales SEK 53.5 M (12.1)
* Operating loss SEK 184.6 M (loss: 202.7)
* Loss after tax SEK 181.6 M (loss: 207.7)
* Loss per share for the year was SEK 3.66 (loss: 4.47)



  For further information, please contact:
  Tomas Leanderson
  President and CEO
  Tel: +46 (0)46-19 20 95

  Göran Forsberg
  VP Investor Relations & Business Development

  Tel: +46 (0)46-19 11 54

  Hans Kolam
  CFO
  Tel: +46 (0)46-19 20 44

  Active Biotech AB
  (Corp. Reg. No. 556223-9227)
  PO Box 724, SE-220 07 Lund
  Tel: +46 (0)46-19 20 00
  Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com

Active Biotech Year End Report Jan-Dec 2008 -- http://hugin.info/1002/R/1289660/290518.pdf

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Contact Information